Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice
暂无分享,去创建一个
[1] M. Farlow,et al. Immunotherapy for Alzheimer's disease. , 2013, Neurologic clinics.
[2] Jürgen Götz,et al. Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.
[3] D. Quartermain,et al. Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model , 2010, The Journal of Neuroscience.
[4] Jürgen Götz,et al. Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.
[5] N. Grigoriadis,et al. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice , 2010, Experimental Neurology.
[6] J. Kril,et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models , 2010, Proceedings of the National Academy of Sciences.
[7] J. Trojanowski,et al. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.
[8] Martin Beibel,et al. Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.
[9] J. Götz,et al. Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease* , 2009, The Journal of Biological Chemistry.
[10] Joanna M. Wardlaw,et al. Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis , 2009, Neurobiology of Aging.
[11] Jürgen Götz,et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia , 2008, Proceedings of the National Academy of Sciences.
[12] N. Cairns,et al. ALS and FTLD: two faces of TDP‐43 proteinopathy , 2008, European journal of neurology.
[13] J. Götz,et al. Divergent phosphorylation pattern of tau in P301L tau transgenic mice , 2008, The European journal of neuroscience.
[14] J. Götz,et al. Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.
[15] Ayodeji A. Asuni,et al. Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.
[16] J. Schneider,et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.
[17] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[18] P. Carvey,et al. Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy , 2007, Cell transplantation.
[19] D. Karussis,et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. , 2006, Archives of neurology.
[20] B. Hyman,et al. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.
[21] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[22] Hirotaka Yoshida,et al. Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.
[23] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[24] R. Nitsch,et al. Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.
[25] W. Kamphorst,et al. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. , 1998, The American journal of pathology.
[26] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[27] D. Selkoe,et al. Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.
[28] H. Braak,et al. Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.
[29] E. Masliah,et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.
[30] D. Selkoe. Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.